V L Krause1, S J Reid, A Merianos. 1. Centre for Disease Control, Territory Health Services, Darwin, NT. vicki.krause@nt.gov.au
Abstract
OBJECTIVE: To examine the epidemiology of invasive pneumococcal disease (IPD) in the Northern Territory of Australia as a basis for optimising vaccination and healthcare provision. DESIGN: Prospective laboratory surveillance, with information collected from hospital and clinic records. SETTING: Northern Territory (NT) and rural communities in north-west South Australia served by an NT hospital, 1994-1998 (NT population is 27% Indigenous). MAIN OUTCOME MEASURES: IPD incidence and mortality, risk factors, clinical presentation and disease-causing serotypes in Indigenous and non-Indigenous people. RESULTS: 425 cases of IPD were detected, with 77% in Indigenous people. IPD incidence was highest in Indigenous children aged < 2 years (1534 per 100,000 in central Australia), but about 100 per 100,000 in non-Indigenous children < 2 years and all Indigenous age groups aged > or = 15 years. Mean ages of those with disease were 39 years in Indigenous people and 48 years in non-Indigenous people (P = 0.006) and, of those who died, 41 and 53 years, respectively (P = 0.04). IPD risk factors were present in 72% of Indigenous and 55% of non-Indigenous patients aged > or = 2 years. Serotype results for 363 isolates showed that the 23-valent vaccine covered 68% and 85% of isolates from Indigenous and non-Indigenous people aged > or = 2 years, respectively, while the proposed seven-, nine- and 11-valent conjugate vaccines covered 58%, 66% and 67% of isolates, respectively, from Indigenous children aged < 2 years and 72% each of those from non-Indigenous children. Case-fatality rates were 10% in both Indigenous and non-Indigenous people. CONCLUSION: These data support the recent change in NT vaccination policy which extended funding for the 23-valent vaccine to all Indigenous people aged > or = 15 years and all Indigenous children in central Australia aged 2-5 years. The high rates of IPD in both Indigenous and non-Indigenous children mandate action to make conjugate vaccine available as soon as possible.
OBJECTIVE: To examine the epidemiology of invasive pneumococcal disease (IPD) in the Northern Territory of Australia as a basis for optimising vaccination and healthcare provision. DESIGN: Prospective laboratory surveillance, with information collected from hospital and clinic records. SETTING: Northern Territory (NT) and rural communities in north-west South Australia served by an NT hospital, 1994-1998 (NT population is 27% Indigenous). MAIN OUTCOME MEASURES: IPD incidence and mortality, risk factors, clinical presentation and disease-causing serotypes in Indigenous and non-Indigenous people. RESULTS: 425 cases of IPD were detected, with 77% in Indigenous people. IPD incidence was highest in Indigenous children aged < 2 years (1534 per 100,000 in central Australia), but about 100 per 100,000 in non-Indigenous children < 2 years and all Indigenous age groups aged > or = 15 years. Mean ages of those with disease were 39 years in Indigenous people and 48 years in non-Indigenous people (P = 0.006) and, of those who died, 41 and 53 years, respectively (P = 0.04). IPD risk factors were present in 72% of Indigenous and 55% of non-Indigenous patients aged > or = 2 years. Serotype results for 363 isolates showed that the 23-valent vaccine covered 68% and 85% of isolates from Indigenous and non-Indigenous people aged > or = 2 years, respectively, while the proposed seven-, nine- and 11-valent conjugate vaccines covered 58%, 66% and 67% of isolates, respectively, from Indigenous children aged < 2 years and 72% each of those from non-Indigenous children. Case-fatality rates were 10% in both Indigenous and non-Indigenous people. CONCLUSION: These data support the recent change in NT vaccination policy which extended funding for the 23-valent vaccine to all Indigenous people aged > or = 15 years and all Indigenous children in central Australia aged 2-5 years. The high rates of IPD in both Indigenous and non-Indigenous children mandate action to make conjugate vaccine available as soon as possible.
Authors: K F O'Grady; J B Carlin; A B Chang; P J Torzillo; T M Nolan; A Ruben; R M Andrews Journal: Bull World Health Organ Date: 2009-12-08 Impact factor: 9.408
Authors: Grant A Mackenzie; Amanda J Leach; Jonathan R Carapetis; Janelle Fisher; Peter S Morris Journal: BMC Infect Dis Date: 2010-10-23 Impact factor: 3.090
Authors: Daniel R Feikin; Eunice W Kagucia; Jennifer D Loo; Ruth Link-Gelles; Milo A Puhan; Thomas Cherian; Orin S Levine; Cynthia G Whitney; Katherine L O'Brien; Matthew R Moore Journal: PLoS Med Date: 2013-09-24 Impact factor: 11.069
Authors: A W Bill Musk; Alan L James; Lyle J Palmer; Gerard F Ryan; Fiona Lake; Clayton L Golledge; Nicholas H De Klerk Journal: Respirology Date: 2008-03 Impact factor: 6.424